Glaukos Corporation $GKOS Stock Holdings Decreased by Vanguard Group Inc.

Vanguard Group Inc. trimmed its position in Glaukos Corporation (NYSE:GKOS) by 1.1% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 6,046,520 shares of the medical instruments supplier’s stock after selling 65,699 shares during the period. Vanguard Group Inc. owned 10.53% of Glaukos worth $493,094,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. UMB Bank n.a. grew its position in shares of Glaukos by 102.6% in the 3rd quarter. UMB Bank n.a. now owns 312 shares of the medical instruments supplier’s stock worth $25,000 after acquiring an additional 158 shares in the last quarter. REAP Financial Group LLC acquired a new stake in shares of Glaukos during the third quarter worth $40,000. AlphaQuest LLC boosted its holdings in shares of Glaukos by 5,754.5% in the 2nd quarter. AlphaQuest LLC now owns 644 shares of the medical instruments supplier’s stock valued at $67,000 after buying an additional 633 shares during the period. SBI Securities Co. Ltd. grew its position in shares of Glaukos by 42.9% during the 3rd quarter. SBI Securities Co. Ltd. now owns 1,205 shares of the medical instruments supplier’s stock valued at $98,000 after buying an additional 362 shares during the last quarter. Finally, Smartleaf Asset Management LLC raised its stake in Glaukos by 16.2% during the second quarter. Smartleaf Asset Management LLC now owns 973 shares of the medical instruments supplier’s stock worth $99,000 after acquiring an additional 136 shares during the period. 99.04% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the company. BTIG Research restated a “buy” rating and issued a $131.00 target price on shares of Glaukos in a research note on Wednesday, February 18th. Stifel Nicolaus boosted their price objective on Glaukos from $115.00 to $160.00 and gave the company a “buy” rating in a research report on Thursday, January 22nd. Truist Financial increased their target price on Glaukos from $120.00 to $145.00 and gave the stock a “buy” rating in a research report on Thursday, December 18th. UBS Group raised their target price on Glaukos from $140.00 to $145.00 and gave the company a “buy” rating in a research note on Tuesday, December 23rd. Finally, Needham & Company LLC upped their price target on shares of Glaukos from $125.00 to $127.00 and gave the stock a “buy” rating in a research report on Wednesday, February 18th. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, Glaukos has an average rating of “Moderate Buy” and an average price target of $133.69.

Insider Buying and Selling

In other Glaukos news, Director Aimee S. Weisner sold 15,000 shares of the business’s stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $117.38, for a total transaction of $1,760,700.00. Following the sale, the director owned 18,806 shares in the company, valued at approximately $2,207,448.28. The trade was a 44.37% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Thomas William Burns sold 186,945 shares of the firm’s stock in a transaction dated Friday, January 16th. The stock was sold at an average price of $115.00, for a total transaction of $21,498,675.00. Following the completion of the transaction, the chief executive officer owned 153,775 shares of the company’s stock, valued at approximately $17,684,125. The trade was a 54.87% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 325,000 shares of company stock valued at $37,739,259 in the last three months. Insiders own 5.80% of the company’s stock.

Glaukos Trading Up 1.7%

Shares of NYSE:GKOS opened at $121.25 on Thursday. The firm has a market cap of $7.04 billion, a P/E ratio of -37.19 and a beta of 0.70. The company has a current ratio of 4.69, a quick ratio of 4.06 and a debt-to-equity ratio of 0.10. Glaukos Corporation has a twelve month low of $73.16 and a twelve month high of $130.23. The company has a 50 day moving average of $115.75 and a 200-day moving average of $99.63.

Glaukos (NYSE:GKOS) last posted its quarterly earnings data on Tuesday, February 17th. The medical instruments supplier reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.06). Glaukos had a negative return on equity of 7.00% and a negative net margin of 36.99%.The firm had revenue of $143.12 million during the quarter, compared to the consensus estimate of $132.16 million. During the same period in the prior year, the firm posted ($0.40) EPS. The firm’s quarterly revenue was up 35.6% on a year-over-year basis. As a group, analysts anticipate that Glaukos Corporation will post -1.08 earnings per share for the current fiscal year.

Glaukos Company Profile

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.